Adoptive cell transfer: a clinical path to effective cancer immunotherapy - Test2 - elhamkhani - TriplyDB

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

http://www.wikidata.org/entity/Q24644774

about

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy Thunder and lightning: immunotherapy and oncolytic viruses collide Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Tumor initiation in human malignant melanoma and potential cancer therapies CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors Engineering approaches for regeneration of T lymphopoiesis CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas Bacteria in Cancer Therapy: Renaissance of an Old Concept Cancer immunotherapy: the beginning of the end of cancer?shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy Single-cell analysis tools for drug discovery and development RNA-Based Vaccines in Cancer Immunotherapy Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling Trial Watch: Adoptive cell transfer for oncological indications Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy Adoptive T-cell therapy for cancer: The era of engineered T cells CAR T cells for solid tumors: armed and ready to go?Preclinical biosafety evaluation of cell-based therapies: emerging global paradigms T lymphocytes targeting native receptors Genetically modified T cells for the treatment of malignant disease Interleukin 12: still a promising candidate for tumor immunotherapy?From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes Genetic engineering with T cell receptors Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook Novel immunotherapies for hematologic malignancies Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy Trial watch: Dendritic cell-based anticancer therapy Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies Advances of immunotherapy in small cell lung cancer Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines Quantifying biomass changes of single CD8+ T cells during antigen specific cytotoxicity Proliferation-linked apoptosis of adoptively transferred T cells after IL-15 administration in macaques Antigen-specific T cells fully conserve antitumour function following cryopreservation.Roles of endothelial A-type lamins in migration of T cells on and under endothelial layers.Differentiation of glioma and radiation injury in rats using in vitro produce magnetically labeled cytotoxic T-cells and MRI PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models

P2860

Q24596055-A6732A47-F595-4AF0-8DD6-4D48FE7A10B7 Q24597894-480CCFBC-1231-414D-8050-1FEC4BF18BF7 Q24623215-AEBF1FCF-0DC5-4C2B-BAD1-6BE8040823E4 Q24634207-F8184FAD-E804-4574-9F84-754296488B9F Q26740520-D4069124-1712-4DFE-BFBE-42393CDDDD46 Q26741260-15F9777A-444F-43BE-AAD6-561A71E9F21D Q26745978-97CDB901-D5B7-4A70-BEA6-A848FED4AFBA Q26749139-6A5277C9-61FF-452F-B681-390AC8A4F1AA Q26751222-BBD2DD78-7829-40C7-9DC1-F553992BEB4A Q26752277-9F7B5199-9CD3-489B-A518-F403C4A4376E Q26765364-5FF81E54-8E3D-4DED-B2B4-E83EBDAE96B5 Q26771192-833EDB24-A4B6-4F40-A8E1-C844287DF6F3 Q26775754-5CCE35D6-0AF5-431C-87CA-46152648F8A4 Q26776028-B4D48668-C504-457A-AD1B-56406ECFE5C1 Q26781643-3ED0C24F-8E2B-431A-A525-C908630F6183 Q26785545-D4260E83-C411-4860-8E7F-9BC0DE7BBB74 Q26798404-AC53193C-69CF-4A35-BBDB-2E6538C25E60 Q26800611-D21FAC5A-76AB-42B3-A25A-9BEAF62E88A6 Q26825489-9C57E810-3A4E-420D-8B19-162B17824983 Q26829230-B1D2643C-9AFF-434D-8A75-36BC8DB5EBB8 Q26853345-39BE6FE4-C114-4E03-973E-B3DEA297C9C5 Q26860657-DD086CD8-BB63-4F80-A4F8-9F45354CAA6F Q26861559-0B350464-E7D4-4295-8D00-257B5A289029 Q26865532-A3848486-60F9-4891-8FEE-5A1BE316ECAD Q26865789-FCE7E688-8842-486C-86AE-6E028FFDDF91 Q26991991-35AC1BAB-1B6D-40A0-ADCD-0A0658FE4A14 Q26995677-57102286-5D1D-4B21-8A66-E286010197EE Q27004178-46333A27-3AD8-4DF7-943B-3C1F7FF417CD Q27004436-C47831BE-3EE5-4065-B67D-99A4DE227348 Q27021570-0B4B9ABE-E670-4D83-8803-DBD419D8BBBA Q27024047-129DA452-7C80-445C-807C-F919631F9B20 Q27027243-361C3868-9FF5-4135-BE93-229DAD425574 Q27027662-7CD1318A-650D-4194-948D-EB7FC64FF6AF Q27030560-64DBD42E-A0E0-471E-BEA1-644379B63444 Q27311367-A5BA699F-6DB8-489E-991B-3A11941743D6 Q27314843-6A2CBBC3-8F6F-4306-A99A-3C62F4D8EA24 Q27323082-870FBDD2-0CC4-469E-91CD-0EBE3709F7EA Q27329601-76C4E518-CB1B-4F20-9933-F58A9D5976E5 Q27334184-07D3C9A3-D413-4325-906C-11C906F4ABB1 Q27339832-99CA2508-246D-4050-BDDC-11E1A29F3879

P2860

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

http://www.wikidata.org/entity/Q24644774

description

2008 nî lūn-bûn

@nan

2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

@ast

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

@en

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

@nl

type

label

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

@ast

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

@en

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

@nl

prefLabel

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

@ast

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

@en

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

@nl

P1433

Q24644774-90712C83-83E8-43A6-B7ED-7A06E1137414

P1476

Q24644774-0668ADF1-F13E-4B84-9508-1CCC83F79A24

P2093

Q24644774-2F05F99E-0EAE-4370-89CF-4C965F286A26

Q24644774-48538F56-195E-43DD-9F2E-F0DC854C7CCC

Q24644774-7795F5EB-C86F-4E55-8C44-5E1625A4A18D

Q24644774-83BC6BC7-DD42-41B9-9733-6E33B9F8CE6F

P2860

Q24644774-000EAA7D-359F-4ABA-9A0A-D79E0A704BD0

Q24644774-027B6893-90C1-4480-BE25-8D3C48E44AEA

Q24644774-049CB753-C262-4AE3-9C88-6273222942CB

Q24644774-06A3471C-E993-43B3-95D9-34F32B3686AA

Q24644774-06CA3AD3-7A23-44FC-A19B-A882EC3267FD

Q24644774-07A6776F-15C3-4B9D-86E2-AE2097AE186A

Q24644774-09DAFC38-9993-45B2-B195-FFD98C43725B

Q24644774-154D4843-CC30-49F7-90AC-01F0BAF5E2C4

Q24644774-1BA2B952-27EB-4CB1-AEED-4CD05EE50F46

Q24644774-253186A8-7A23-4092-B063-185D5A4C6934

P2888

Q24644774-D13964C0-45AB-4D91-817B-CB6EC47025E7

P304

Q24644774-870EDF0C-9D12-4032-9879-4648D03525E8

P31

Q24644774-E219CB12-B530-4B1E-A2EB-16DBDB20909E

P3181

Q24644774-89F1DE1A-B3A6-4BC1-9064-51B3F8F56C6B

P356

Q24644774-493BE865-7D92-4A8C-B455-AFFC3CEBF037

P407

Q24644774-4202CD6F-22EA-46CD-80E5-2D16B2084918

P433

Q24644774-2E37B8A5-FCC7-4F95-9530-227BD1E01929

P478

Q24644774-9175BA45-DFC3-4113-9578-E23B1D6BF354

P50

Q24644774-0D91290A-F74B-4B34-8393-0779E4492D48

P577

Q24644774-11AB0403-DF7C-4A49-8DC9-2816369C91A8

P5875

Q24644774-1CE76B25-6CEC-434C-A8D5-2D7566919358

P6179

Q24644774-328C19C4-78C9-4EFF-A633-84EB9A40C52B

P698

Q24644774-494D5115-0B15-4485-8E5C-071AA0BD341E

P921

Q24644774-355CA79A-67A9-4BFF-83D5-D69DB0AD42D0

P932

Q24644774-B93DC94A-FACE-4D2B-A36E-1F0A4669CD8D

P3181

P356

P1433

Nature Reviews Cancer

P1476

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

@en

P2093

James C Yang

http://www.w3.org/2001/XMLSchema#string

Mark E Dudley

http://www.w3.org/2001/XMLSchema#string

Richard A Morgan

http://www.w3.org/2001/XMLSchema#string

Steven A Rosenberg

http://www.w3.org/2001/XMLSchema#string

P2860

A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Cancer immunotherapy: moving beyond current vaccines

T cell homeostatic proliferation elicits effective antitumor autoimmunity

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Cancer regression in patients after transfer of genetically engineered lymphocytes

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

P2888

P304

299-308

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

389235

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NRC2355

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas P. Restifo

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5498883

http://www.w3.org/2001/XMLSchema#string

P6179

1050199541

http://www.w3.org/2001/XMLSchema#string

P698

18354418

http://www.w3.org/2001/XMLSchema#string

P921

P932

2553205

http://www.w3.org/2001/XMLSchema#string